Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AEye (LIDR) Asset Writedowns and Impairment (2021 - 2025)

AEye (LIDR) has disclosed Asset Writedowns and Impairment for 5 consecutive years, with $2000.0 as the latest value for Q2 2025.

  • On a quarterly basis, Asset Writedowns and Impairment fell 90.0% to $2000.0 in Q2 2025 year-over-year; TTM through Sep 2025 was -$33000.0, a 100.33% decrease, with the full-year FY2023 number at $10.0 million, changed N/A from a year prior.
  • Asset Writedowns and Impairment was $2000.0 for Q2 2025 at AEye, up from -$35000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $9.9 million in Q4 2023 to a low of -$576000.0 in Q4 2022.
  • A 5-year average of $932750.0 and a median of $17000.0 in 2024 define the central range for Asset Writedowns and Impairment.
  • Peak YoY movement for Asset Writedowns and Impairment: crashed 147.88% in 2022, then surged 1825.87% in 2023.
  • AEye's Asset Writedowns and Impairment stood at $1.2 million in 2021, then plummeted by 147.88% to -$576000.0 in 2022, then soared by 1825.87% to $9.9 million in 2023, then plummeted by 100.35% to -$35000.0 in 2024, then surged by 105.71% to $2000.0 in 2025.
  • Per Business Quant, the three most recent readings for LIDR's Asset Writedowns and Impairment are $2000.0 (Q2 2025), -$35000.0 (Q4 2024), and $1000.0 (Q3 2024).